Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Japan.
Acta Haematol. 2012;127(1):10-5. doi: 10.1159/000330950. Epub 2011 Oct 7.
Angioimmunoblastic T cell lymphoma (AITL) is a rare subtype of T cell non-Hodgkin lymphoma. The standard therapeutic strategy for AITL has not yet been established, and its prognosis remains poor. This report concerns the effect of cyclosporin A (CsA) on chemotherapy-refractory AITL. A 68-year-old female with AITL with systemic symptoms, such as high fever, skin rash and generalized lymphadenopathy, was initially treated with conventional cytotoxic chemotherapies using alkylators, anthracyclines and corticosteroids, which failed to induce remission. However, CsA (4 mg/kg/day) plus dexamethasone treatment resulted in a dramatic regression of the tumors and amelioration of systemic symptoms and induced complete remission (CR) within 2 weeks. Currently, the patient's CR has continued for more than 18 months with CsA maintenance therapy. Our experience and previously reported findings suggest that CsA may constitute an alternative treatment option for AITL, even though the use of conventional cytotoxic chemotherapy continues to be the first-line therapy on an empirical basis.
血管免疫母细胞性 T 细胞淋巴瘤（AITL）是一种罕见的 T 细胞非霍奇金淋巴瘤亚型。AITL 的标准治疗策略尚未确立，其预后仍然较差。本报告关注环孢素 A（CsA）对化疗耐药性 AITL 的影响。一名 68 岁女性患有 AITL，伴有高热、皮疹和全身淋巴结病等全身症状，最初接受常规细胞毒性化疗，包括烷化剂、蒽环类药物和皮质类固醇，但未能诱导缓解。然而，CsA（4mg/kg/天）加地塞米松治疗导致肿瘤显著消退，全身症状改善，并在 2 周内诱导完全缓解（CR）。目前，患者的 CR 已持续超过 18 个月，接受 CsA 维持治疗。我们的经验和先前的报告结果表明，即使基于经验的常规细胞毒性化疗仍然是一线治疗，CsA 也可能成为 AITL 的另一种治疗选择。
